The New CHEST Guidelines on Antithrombotic Therapy for Atrial Fibrillation Should Consider Recent Data on Rivaroxaban
Journal
Chest
Journal Volume
155
Journal Issue
6
Pages
1309-1311
Date Issued
2019
Author(s)
Kim Y.-H.
Shim J.
Wang C.-C.
Vilela G.
Muengtaweepongsa S.
Kurniawan M.
Maskon O.
Hsu L.F.
Nguyen T.H.
Sim K.
Camm A.J.
SDGs
Other Subjects
anticoagulant agent; antivitamin K; apixaban; dabigatran; edoxaban; rivaroxaban; warfarin; anticoagulant agent; fibrinolytic agent; warfarin; anticoagulant therapy; Asian; atrial fibrillation; bleeding; cerebrovascular accident; drug efficacy; drug safety; evidence based medicine; human; Letter; meta analysis (topic); phase 3 clinical trial (topic); practice guideline; priority journal; Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Humans; Rivaroxaban; Warfarin
Publisher
Elsevier Inc
Type
letter